Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives
| Autor: | Suvina Amin, Sara M Tolaney, M Janelle Cambron-Mellott, Kathleen Beusterien, Martine C Maculaitis, Emily Mulvihill, Reshma Shinde, Kimmie McLaurin |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Future Oncology. 18:1927-1941 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | The goal of this study was to understand the preferences of patients and physicians for the benefits and risks associated with the treatment of advanced breast cancer that expresses normal amounts of the HER2 protein (termed as HER2 negative). Respondents completed an exercise where they compared two treatment options at a time that varied in their level of effectiveness and their potential for certain side effects and then selected the treatment option they most preferred. From this exercise, the treatment features that matter the most to patients and physicians were discovered. The most important treatment features for patients were lengthening life expectancy, decreasing the chance of experiencing nausea affecting appetite, and decreasing the chance of experiencing nerve damage involving numbness and/or pain, possibly severe, in hands and feet which may limit daily activities. The most important treatment features for physicians were lengthening life expectancy, decreasing the change of experiencing nerve damage involving numbness and/or pain, possibly severe, in hands and feet which may limit daily activities, and lengthening the time that cancer remains stable and does not worsen. Patients and physicians also rated how much they agreed with statements about their goals for treatment. While 67% of oncologists believed that their patients are more focused on killing the cancer than their quality of life, only 27% of patients were more focused on killing the cancer than their quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|